Anti-Mouse CD366 (Tim-3) – Purified (PhenoCyler-Fusion (CODEX)® Ready)

Clone RMT2-23 has been validated for use on CODEX® using mouse T-cell Sarcoma fresh frozen (FF) tissue.

This antibody was produced using recombinant mouse TIM-3

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4.

This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

AB_2892983

Clone RMT2-23 recognizes an epitope on mouse Tim-3.

Tim-3 is expressed on activated Th1 and Tc1 lymphocytes, CD11b+ macrophages, Tregs, NK cells, and mast cells.

Tim-3 antibody, clone RMT3-23, recognizes T cell immunoglobulin and mucin domain-containing protein 3 (TIM3, also known as CD366), a TIM family member of immunoregulatory proteins. Tim-3 is a 60kDa type I transmembrane protein with an extracellular immunoglobulin and mucin-like domain and a cytoplasmic tyrosine phosphorylation motif. Tim-3 is expressed by IFNg-producing Th1 CD4 and Tc1 (cytotoxic) CD8 T cells¹, regulatory T cells (Tregs)², myeloid cells³, NK cells⁴, and mast cells⁵. Tim-3 is an inhibitory molecule that limits Th1-mediated inflammatory diseases, including a model of central nervous system inflammation (experimental autoimmune encephalomyelitis, EAE)¹, inflammatory bowel disease (IBD)⁶, and type I diabetes⁷. Tim-3 is also proposed to induce immunological tolerance⁷, promote Th1 apoptosis⁸, and regulate macrophage activation1. In addition, Tim-3 is upregulated on tumor-infiltrating lymphocytes, and coblockade of Tim-3 and immune checkpoint inhibitors, such as PD-1, is currently being investigated in clinical trials for the treatment of cancer⁹.

Putative ligand on resting CD4+ lymphocytes

May play a role in the development of immune responses and the development of Th1-mediated responses

1. Monney, L. et al. (2002)Nature 415, 536–541.
2. Gao, X. et al. (2012) PLOS ONE 7, e30676.
3. Anderson, A. C. et al. (2007) Science 318, 1141–1143.
4. Ndhlovu, L. C. et al. (2012) Blood 119, 3734–3743.
5. Phong, B. L. et al. J. (2015) Exp. Med. 212, 2289–2304.
6. Li, X. et al. (2010) Clin. Immunol. 134, 169–177.
7. Sanchez-Fueyo, A. et al. (2003) Nat. Immunol. 4, 1093–1101.
8. Zhu C, et al.. Nature Immunology. 2005;6:1245–1252.